Stakeholder Actions to Generate Better Real-World Evidence for HTA and Payers
The 26th of March 2024 RWE4Decisions webinar discussed the revision of the 2020 paper “Real-world Evidence to Support Payer/HTA Decisions about Highly Innovative Technologies in the EU – Actions for Stakeholders”, available here. Together with the RWE4Decisions Learning Network, a new set of Actions for each stakeholder group has been drafted and presented at the webinar. […]
Real-World Evidence over the Medicine’s Lifecycle to Inform HTA/Payer Decisions
BIP Meeting Center (Room ‘Salles des Guichets’), Rue Royale 2-4, 1000 Bruxelles
RWE over the lifecycle of ATMPs to meet the HTA (Regulation) Needs
Join us on 10 October for the RWE4Decisions webinar on how RWE over the lifecycle of ATMPs could support the EU joint HTA work. You will hear from Prof Ana Hidalgo-Simon, who will set the scene on the clinical and regulatory context for ATMPs in the EU. A multi-stakeholder panel will then follow, representing the […]
Beating Cancer with Highly Innovative Technologies – What’s the role of RWE?
Join us on 18 April for the first webinar on using RWE to demonstrate the value of cancer treatments. A keynote address will outline the EU policy context in terms of the Beating Cancer Plan. A panel including policy, clinical, patient, industry and HTA experts will then discuss the opportunities and challenges of RWE generation […]
Public webinar series | Supporting HTA/Payer decision-making: Health data initiatives in Germany
On 21 September 2022, the RWE4Decisions community gathered for a multi-stakeholder discussion on HealthData in Germany, with a focus on the routine data collection practice (AbD) at the Federal Joint Committee (G-BA). The panel featured representation of HTA bodies, patients, insurers and industry.
Public Webinar Series | Supporting HTA/Payer decisions making: National health data initiatives in Finland, Spain and France
On 21 September 2022, the RWE4Decisions community gathered for a multi-stakeholder discussion on HealthData in Germany, with a focus on the routine data collection practice (AbD) at the Federal Joint Committee (G-BA). The panel featured representation of HTA bodies, patients, insurers and industry.
Towards Establishing an EU Real-World Evidence Generation Action Plan for Better Healthcare Systems & Patient Outcomes
The need for an EU Real-World Evidence (RWE) Generation Action Plan was a key conclusion from the 2020 RWE4Decisions Conference held under the auspices of the German EU Presidency. This call was taken up in the June EPSCO Council Conclusions on Access to Medicines under the Portuguese EU Presidency.
The Use of Real-World Evidence for Decision-Making: Next Steps to Develop HTA Guidance
In this webinar organized by the RWE4Decisions multi-stakeholder initiative, consideration will be given to methodological recommendations on generation and use of real-world evidence (RWE) in pricing and reimbursement decision-making with a view to identifying what steps need to be taken to align on the way forwards. Guidance can act as a roadmap to generate high-quality RWE, […]
Delivering a Health Data Strategy for the European Reference Networks
Since their inception in 2017, European Reference Networks (ERNs) have started building-up the evidence base for the natural history of rare diseases, starting with ERN registries and disease specific health outcomes. However, the full potential of ERNs can only be realised if they are able to combine and link different types of data from different sources, […]
Co-Creating RWE Excellence for Decision-Making: Meeting Regulatory and HTA/Payer Needs
In the first webinar – held on 22 April 2021 – we discussed the implications of the EMA’s Guidelines across the HTA/Payer world on study designs, methodologies and for the future applicability of RWE requirements. Consideration was also given to whether cross-country and cross-stakeholder collaboration should aim to achieve convergence of guidelines, metrics and methodologies […]